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GENOMIC SOVEREIGNTY OR THE ENEMY WITHIN
 
Jesús Mario Siqueiros-García1, Pablo Francisco Oliva-Sánchez1, Garbiñe Saruwatari-Zavala1
Abstract: Genomic sovereignty is a concept that has become very popular among developing countries such as India, China, 
South Africa and Mexico. This concept is a response to developed countries that have taken advantage of those countries 
and researchers who don’t have the means for protecting their own biogenetic resources. In this article we argue that 
genomic sovereignty is not about the “others” extracting and exploiting local  “human genetic resources”, but developing 
and implementing the ethical, legal and administrative tools, based on transparency, openness and equal access to biological 
material, in order to build up a robust research networks.  Being biological samples a scarce and valuable good, we conclude 
that controlling the access to this resource by means of the law, without a well implemented biobanking system and a clear 
scientific policy may lead to a situation where asymmetric relations are generated among research groups of the very same 
developing country. We would advice to those countries pretending to protect their biological samples and data from the 
outside, before developing laws against possible “intrusions”, they need to design strategies to promote equal and fair access 
to both resources paramount to biomedical research.
Key words: genomic sovereignty, Mexico, law, research communities, developing countries, biological samples, cultural 
values, biobanks ethics
Soberanía genómica o el enemigo interior
Resumen: “Soberanía genómica” es un concepto que se ha hecho muy popular entre los países en desarrollo, como India, 
China, Sudáfrica y México. Este concepto es una respuesta a los países desarrollados que han tomado ventaja, aprovechándose 
de aquellos países y de los investigadores que no tienen los medios para proteger sus propios recursos biogenéticos. En este 
artículo argumentamos que la soberanía genética no se trata de impedir que “otros” extraigan y exploten “los recursos genéticos 
humanos” locales, sino del desarrollo y de la aplicación de las herramientas éticas, jurídicas y administrativas basadas en la 
transparencia, la apertura e igualdad en el acceso al material biológico, con el fin de construir redes de investigación sólidas. 
Al ser las muestras biológicas un bien escaso y valioso, concluimos que el control del acceso a este recurso, por medio de la 
ley, sin un sistema de biobancos bien implementado y sin una política científica clara, puede llevar a una relación asimétrica 
entre los grupos de investigación del mismo país en desarrollo. Nos gustaría advertir a los países que pretenden proteger sus 
muestras biológicas y datos asociados que, antes que elaborar leyes contra posibles intrusiones, es necesario diseñar estrategias 
para promover el acceso justo y equitativo a los recursos primordiales para la investigación biomédica.
Palabras clave: soberanía genómica, México, ley, comunidades de investigación, países en desarrollo, muestras biológicas, 
valores culturales, ética de biobancos
Soberania genômica ou o inimigo interior
Resumo: “Soberania genômica” é um conceito que se fez muito popular entre os países em desenvolvimento, como Índia, 
China, África do Sul e México. Este conceito é uma  resposta aos países desenvolvidos que obtiveram vantagem, aproveitando-
se daqueles países e dos investigadores que não têm meios para proteger os seus próprios recursos biogenéticos. Neste artigo 
argumentamos que a soberania genética não trata de impedir que “outros” extraiam e explorem “os recursos genéticos humanos” 
locais, senão do desenvolvimento e da aplicação das ferramentas éticas, jurídicas e administrativas baseadas na transparência, 
abertura e igualdade no acesso ao material biológico, com a finalidade de construir redes de investigação sólidas. Por serem as 
amostras biológicas um bem escasso e valioso, concluimos que o controle do acesso a este recurso, por meio da lei, sem um 
sistema de biobancos bem implementado e  sem uma política científica clara, pode levar a uma relação assimétrica entre os 
grupos de investigação de um mesmo país em desenvolvimento. Gostaríamos advertir aos países que pretendem proteger suas 
amostras biológicas e dados associados que, antes de elaborar leis contra possíveis intromissões, é necessário projetar estratégias 
para promover o acesso justo e equitativo aos recursos primordiais para a investigação biomédica.
Palavras-chave: soberania genômica, México, lei, comunidades de investigação, países em desenvolvimento, amostras biológicas, 
valores culturais, ética de biobancos
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Introduction
“Genomic sovereignty is the capacity of a people, 
a country or nation to own, to control both ac-
cess to and use of, samples, data and knowledge 
concerning or emanating from  genomic mate-
rial”(1). This is a broad definition and it reflects 
the essence of the idea. Altogether, it is important 
to mention too, that this is a concept that emer-
ges from those who feel the need to protect their 
biogenetic resources from third parties to exploit 
them. 
Acknowledging such nuances, genomic sovere-
ignty is a concept that is popular among certain 
countries and some of them are pursuing it, or 
at least that is what could be perceived during 
the 12th International Congress of Human Ge-
netics that took place in Montreal last October. 
Dr. Charles Rotimi, one of the most prominent 
promoters of Genomics in Africa, emphasized 
the importance of it in Africa by means of the 
control of access of biological samples and data. 
He mentioned India, China and Mexico as those 
countries who had already implemented it and 
the latter as leader in this subject. 
For Mexico, genomic sovereignty discourse had a 
first order role in promoting among congressmen 
and in convincing them about the importance 
of the Genomic Medicine Project, including the 
creation of the National Institute of Genomic 
Medicine. One day after Dr. Rotimi’s presenta-
tion, in the same Congress we gave a talk about 
Mexico’s quirks with its legal framework regar-
ding genomic sovereignty. With this subject in 
mind, in this article our main argument is that for 
Mexico and probably for other developing coun-
tries, genomic sovereignty is not about ‘others’ ex-
tracting and exploiting local resources regardless 
the sovereignty of the local, but about local scien-
tific communities cultural and moral values and 
the capacity to build a strong  research network 
to exploit (biological samples) national resources.
Historical review
In 1999, ten years after the Human Genome 
Project was launched, four Mexican institutions 
started working together on the Genomic Medi-
cine and National Institute of Genomics project. 
This group included the Ministry of Health (SS), 
the National Council of Science and Technology 
(CONACyT), the National Autonomous Uni-
versity of Mexico (UNAM), and the Foundation 
of Health (FUNSALUD). By 2001, it was known 
as the Consortium to Promote Genomic Medici-
ne. By 2004 the National Institute of Genomic 
Medicine was born and in 2008, the Mexican Se-
nate discussed and added an amendment to the 
General Health Act (GHA), regarding the protec-
tion of biogenetic material from being transferred 
out of Mexico. 
Since the very beginning of the project, the Con-
sortium considered vital to gain control over the 
Mexican genetic diversity as a “natural resource” 
by means of a legal instrument. Nevertheless, it 
was until 2008 that a legal instrument became 
a real necessity due to situations in which DNA 
samples were taken out of the Country without 
Mexico being part of those projects or without 
consent by the Mexican authorities(2).
The argument in favor of the protection of the 
Mexican unique genetic profile persuaded con-
gressmen to work on a set of amendments to the 
GHA, that without being a Law are known as the 
Genomic Sovereignty Law. The concept of sove-
reignty is well rooted in the Mexican nationalistic 
discourse and it’s linked to a postcolonial stance. 
The protection of biological samples was justified 
to the congressmen by saying that being the Mexi-
can population genetically different, we wouldn’t 
be able, as a country to import genomic medicine 
based on others populations genetic profile, and 
still, this genetic profile is valuable for research. 
Outstanding to all justifications was the idea of 
giving an ideological value to the Mexican genetic 
uniqueness by means of the identity discourse of 
the mestizo(2-5).
The Genomic Sovereignty Law had the intention 
to prevent outsiders of taking advantage of the 
“natural resources” as it had been done in the past 
in Mexico’s history (some examples such as petro-
leum, archaeological exploration and the use of 
biodiversity resources by multinational industries 
were cited) by regulating access to human biolo-
gical samples, all of this under the premise that 
the Mexican genome had to be studied by and for 
Mexicans (primarily)(5).
 271
Acta Bioethica  2013; 19 (2): 269-273
According to the Mexican Law, a natural resour-
ces is a natural element that can be exploited for 
the benefit of man(6). But as such, in the con-
text of the stakeholders discourse, the Mexican 
population’s genetic material was conceived as a 
“national good”, that is, as a natural resource that 
would belong to Mexico, that cannot be privati-
zed by anyone or only under very specific circum-
stances, and that its use and exploitation should 
benefit all Mexicans.2 This way of conceiving 
the genetic material of the Mexican population 
would go very well along with the already existing 
discourse of Mexico’s Sovereignty.
Under this vision of genomic sovereignty, in 
2008, congressmen approved the genomic sove-
reignty amendments to the GHA that established 
that genomics studies must be part of a scientific 
research project, that biological samples, intended 
for population Genomic studies, can’t be transferred 
out of Mexico if it is not part of a Mexican scientific 
project; and finally, that anyone who takes biolo-
gical samples (from which DNA can be extracted 
for population genomics studies) will be sanctio-
ned with prison and a fine(7). 
The problem as we see it, was that while focu-
sing on the control over biological samples, con-
gressmen and stakeholders didn’t acknowledge 
the complexities of the genomic enterprise and 
ignore its social, economical, and political dimen-
sions. They failed in developing the right policies 
to accomplish the desired sovereign scientific pro-
ject because access to samples and data could es-
cape by so many different ways, legal and factual. 
So far, the LGS is non-operative due to the abs-
ence of the administrative instruments to apply 
it. Still, there is more, the legal status of biologi-
cal samples is not clear and they fit in more than 
one legal category in the Mexican legal frame, for 
example samples can be a national good where, 
again it fits in different overlapping concepts such 
as common good, State goods, goods for public 
service of the State, moveable property, private 
property. Biological samples can be conceptua-
2 The sovereignty discourse has an excellent example in the case of 
petroleum as a national resource on which Mexico is sovereign. In 
1938, President Cardenas expropriated the oil from foreign companies 
(American, British, and Dutch),  since then, it has been a motive of 
proud Mexico’s sovereignty over its petroleum, as well as a taboo among 
congressmen and possible Mexican stakeholders to propose to open the 
Mexican state-owned  petroleum company to foreign investment.
lized as a natural resource, where human DNA 
could be part of the country’s biodiversity. In 
Mexico’s legal frame, there is no reference to the 
possible research, clinical, forensic, parental tests 
and economical use of samples. In this regard we 
believe that the legal fuzziness of biological sam-
ples makes control over genetic diversity a fuzzy 
matter.
Discussion
From our experience, genomic sovereignty is not 
about the control over biological samples, but 
about having the tools to exploit these resources. 
By tools we refer not only to the necessary tech-
nologies for whole genome sequencing, exome 
sequencing, mRNA (transcriptome), etcetera, 
instead, we are talking about developing and im-
plementing the ethical, legal and administrative 
tools for building up a robust research network. 
For those countries claiming sovereignty (most of 
them developing countries), robustness must be 
designed to get the more from the less by means 
of transparency, openness, inside network pre-
ferential cooperation, and network exchange of 
samples and data, software and knowledge (re-
producible experiments and reports). 
It has been said so many times that genomic so-
vereignty is about preventing the exploitation of 
one country’s populations samples by developed 
countries research institutions based on a asym-
metrical relationship which leads to an unfair, 
unjust situation for the ‘donor’ country. As once 
said by a group of Mexican researchers at the very 
beginning of the Mexican Genomic Medicine 
Project:
“It is urgent to issue a legislation that allows the 
gene pool of Mexican populations to be studied 
through cutting edge technologies in our coun-
try and by national researchers. Our populations, 
isolated and highly related and very genetically 
homogeneous, allow the isolation and identi-
fication of disease genes more easily. Therefore, 
high priority should be given to the collection 
and study of Mexican germplasm by scientists of 
our country, without prejudice to international 
collaborations, preventing this national resource 
to be studied, classified and used almost exclusi-
vely by researchers from other countries like has 
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happened in the past, for example, in archeology, 
wildlife and flora”(5).
For Aréchiga and collaborators the problem is 
quite clear and it seems that is the same pro-
blem for the countries interested in protecting 
their population’s DNA. As it has been mentio-
ned elsewhere, this is a postcolonial matter, it’s 
about not letting others who have, traditionally, 
been taking advantage of those who don’t have 
the means for protecting their resources as well as 
themselves(2,4).
Our point of view regarding genomic sovereignty 
is that it is not (at least primarily) about those 
researchers and their institutions coming from a 
wealthy Country trying to get all what they can 
from poor countries, with a sloppy and weak le-
gislation that makes them vulnerable. What we 
propose is that, even if it is important to set rules 
on how international collaborations are to take 
place, the main problem may lay inside the natio-
nal research communities. 
The Mexican Genomic Sovereignty Law so far 
is not operative because the administrative and 
institutional procedures have not been develo-
ped and implemented yet. In order for Mexican 
researchers to keep collaborating with overseas 
institutions they have had to look for other ‘le-
gal’ ways to go around the limitations imposed 
by this situation. Looking for other ‘legal’ options 
to skip the problems posed by the current state 
legislation on genomic sovereignty might lead to 
malpractice regarding biological samples mana-
gement and to research malpractice as well, not 
to mention that genomic sovereignty might be at 
stake and it becomes a second order concern, ma-
king the Law irrelevant.
We suggest that lawmakers should be focused in 
the creation of the legal instruments to develop 
strong research networks. We also suggest that 
research networks are not only a matter of law 
and policies; in order to generate such networks, 
it is necessary to understand what are the domi-
nant moral and cultural values as well as its prac-
tices in scientific communities. It would be very 
important to understand how those values and 
practices emerge, and what is the role they play 
in articulating or fragmenting research commu-
nities. Culture (values and practices) may play a 
big part in developing a robust research network 
and making genomic sovereignty real (if that is 
what really matters). It is about the importance 
of cooperation, so it is paramount to know if sha-
ring and exchanging data is relevant, what are the 
factual rules for sharing and exchanging biologi-
cal samples and data, and who cooperates with 
who and why.
What is at stake here is that controlling biologi-
cal samples by means of the Law, without a pre-
viously well implemented biobanking system and 
a clear scientific policy, can lead to a bigger pro-
blem than what it pretends to prevent, for exam-
ple, biological samples are absolutely necessary 
for genomics research and they are also a scarce 
good, for which they can be an object that gene-
rates power asymmetry relations among research 
groups. Regarding data, as far as we know, it is 
out of reach of genomic sovereignty domain, but 
what would a biological sample be if not the locus 
of information. Data needs to be shared preferen-
tially among the research networks.
Final remarks
What can be learned from the Mexico’s genomic 
sovereignty project experience is that instead of 
trying to develop a Genomics research system 
based on the control over one simple object, the 
strategy should start acknowledging that the Ge-
nomic enterprise is complex:
•	 It involves different omic approaches (and is 
not only about population genomics).
•	 There are different ends of the omic approa-
ches (health, research, forensics, economical, 
educational).
•	 The meaning of concepts change in different 
contexts (scientific, legal, commercial, ethi-
cal, healthcare, etcetera, to mention them in 
the broadest sense).
•	 Social dynamics of Science are important 
(imply epistemic, moral and ethical, social 
values). 
•	 There are Ethical, Legal and Social issues of 
science that have an impact on society and 
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that need to be taken into account.
To those countries pretending to protect their 
biological samples and data from the outside, 
we would say that before developing laws against 
possible ‘intrusions’, they need to design stra-
tegies to promote equal and fair access to both 
samples an data. Unfair and unequally access to 
them promotes the entrenchment of power rela-
tionships among local research groups, but, to the 
worse, it allows the entrenchment of certain cul-
tural practices in scientific communities, making 
more difficult to change them into good practices. 
Power disparities may also lead powerful groups 
to increase their power, for example, groups with 
preferential access to biological samples might be 
the ones with the possibility of establishing part-
nerships with important research groups from de-
veloped countries. Preventing the dominance of 
some research groups over samples would be the 
first step in building a strong research network. 
Our final statement is that wrongly designed and 
implemented laws affecting scientific research so-
mehow, may lead to scientific malpractice. 
Acknowledgments
We wish to thank Dr. Sergio Litewka for his com-
ments and suggestions. Support from the Pan 
American Bioethics Initiative, Fogarty Internatio-
nal Center-NIH #1R25TW008186 is gratefully 
acknowledged.
References
1. Slabbert MN, Pepper MS: “A room of our own?” Legal lacunae regarding genomic sovereignty in South Africa. Tyds-
krif vir Hedendaagse Romeins‐Hollandse Reg. Journal of Contemporary South African Roman‐Dutch Law 2010; 73: 
432‐450.
2. Schwartz-Marín E. Protegiendo el “Mextizaje”: INMEGEN y la Construcción de la Soberanía Genómica. In López-
Beltrán C, (ed.) Genes (&) Mestizos. UNAM-IIF, Editorial Ficticia; 2011: 155-184.
3. Schwartz-Marín E, Silva-Zolezzi I. The Map of the Mexican’s Genome: Overlapping National Identity, and Population 
Genomics. Identity in the Information Society 2010; 3(3): 489-514.
4. Benjamin R. A lab of their own: Genomic sovereignty as postcolonial science policy. Policy and Society 2009; 28: 341-
355.
5. Aréchiga H, et al. El proyecto del genóma humano: perspectivas de la medicina genómica. Rev Fac Med UNAM 2000; 
43(5): 202-205.
6. México. Cámara de Diputados del H. Congreso de la Unión. Ley General del Equilibrio Ecológico y la Protección al 
Ambiente. Diario Oficial de la Federación, 28 de enero de 1988.
7. México. Cámara de Diputados del H. Congreso de la Unión. Decreto por el que se reforma la fracción V del artículo 
100 y el artículo 461, y se adicionan los artículos 317 Bis y 317 Bis 1, todos de la Ley General de Salud. Diario Oficial 
de la Federación, 14 de julio de 2008. 
Received: March 21, 2012 
Accepted: May 23, 2012
